Efficacy and Feasibility of Time-restricted Eating on Cardiometabolic Health in Adults With Overweight/Obesity (EXTREME)
Efficacy and Feasibility of Time-restricted Eating on Cardiometabolic Health in Adults With Overweight/Obesity: The EXTREME Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Jonatan R. Ruiz, PhD
- Phone Number: 0034958242754
- Email: ruizj@ugr.es
Study Locations
-
-
-
Granada, Spain, 18011
- University of Granada
-
-
Navarra
-
Pamplona, Navarra, Spain, 31006
- Universidad Pública de Navarra
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Aged 30-60 years.
- Body mass index ≥25.0 and <40 kg/m2
- Weight stability (within 3% of screening weight) for >3 months prior to study entry.
- Sedentary lifestyle (<150 min/week of moderate-vigorous intensity exercise) for >3 months prior to study entry.
- Habitual eating window ≥12 hours.
At least one of the following metabolic impairments:
- High-density lipoprotein (HDL) cholesterol concentration <50 mg/dL for females and <40 mg/dL for males.
- Low-density lipoprotein (LDL) cholesterol levels >100 mg/dL (or on medication to treat elevated LDL cholesterol levels).
- Serum triglycerides concentration ≥150 mg/dL or on medication to treat elevated triglycerides.
- Systolic blood pressure >130 mm Hg and/or diastolic blood pressure >85 mm Hg or already being treated with anti-hypertension medications.
Impaired glucose tolerance is defined as at least one of the following:
- Fasting plasma glucose (PG) >100 mg/dL and <125 mg/dL.
- Hemoglobin A1c between ≥5.7% and <6.5%.
- Insulin resistance as measured by the Homeostatic Model Assessment of Insulin Resistance (HOMA2-IR) >1.8.
Exclusion Criteria:
- History of a major adverse cardiovascular event, clinically significant kidney, endocrine, or neurological disease, bariatric surgery, HIV/AIDS, known inflammatory and/or rheumatologic disease, cancer, or other medical condition in which fasting or exercise is contraindicated.
- Type 1 or Type 2 diabetes.
- Major psychiatric disorders, eating disorders, sleep disorders, or alcohol abuse.
Regular use of medication or compounds that may affect study outcomes (e.g., antidiabetic, steroids, beta-blockers, antibiotics, prebiotics, probiotics and symbiotics).
- Participating in a weight loss or a weight-management program.
- Pregnancy and lactation or planned pregnancy (within the study period).
- Caregiver for a dependent requiring frequent nocturnal care/sleep interruptions. Shift workers with variable hours (e.g., nocturnal). Frequent travel over time zones during the study period.
- Fear of needles and claustrophobia to magnetic resonance imaging (MRI).
- Being unable to understand and to accept the instructions or the study objectives and protocol.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Early time-restricted eating
Participants will eat ad libitum within an 8-hour early eating window.
The first meal will be before 10 am (last meal before 18h).
No calorie-containing food or beverage intake will be allowed outside the 8-hour eating window.
Participants will also receive standard recommendations on healthy lifestyle based on Mediterranean dietary pattern and physical activity recommendations for weight loss and health promotion
|
Participants will eat ad libitum within an 8-hour early eating window starting not later than 10am.
No calorie-containing food or beverage intake will be allowed outside the 8-hour eating window.
Participants will also receive standard recommendations on healthy lifestyle based on Mediterranean dietary pattern and physical activity recommendations for weight loss and health promotion
|
|
Experimental: Late time-restricted eating
Participants will eat ad libitum within an 8-hour late eating window.
The first meal will be at 13h or later (last meal not before 21h).
No calorie-containing food or beverage intake will be allowed outside the 8-hour eating window.
Participants will also receive standard recommendations on healthy lifestyle based on Mediterranean dietary pattern and physical activity recommendations for weight loss and health promotion
|
Participants will eat ad libitum within an 8-hour late eating window starting not earlier than 1pm.
No calorie-containing food or beverage intake will be allowed outside the 8-hour eating window.
Participants will also receive standard recommendations on healthy lifestyle based on Mediterranean dietary pattern and physical activity recommendations for weight loss and health promotion
|
|
Experimental: Self-selected time-restricted eating
Participants will self-selecte an 8-hour eating window to eat ad libitum.
No calorie-containing food or beverage intake will be allowed outside the 8-hour eating window.
Participants will also receive standard recommendations on healthy lifestyle based on Mediterranean dietary pattern and physical activity recommendations for weight loss and health promotion
|
Participants will self-selected an 8-hour eating window to eat ad libitum.
No calorie-containing food or beverage intake will be allowed outside the 8-hour eating window.
Participants will also receive standard recommendations on healthy lifestyle based on Mediterranean dietary pattern and physical activity recommendations for weight loss and health promotion
|
|
No Intervention: Usual-care group
Participants will receive standard recommendations on healthy lifestyle based on Mediterranean dietary pattern and physical activity recommendations for weight loss and health promotion
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in visceral adipose tissue
Time Frame: Change from baseline to 12 weeks
|
Visceral adipose tissue will be assessed by Magnetic Resonance Imaging (MRI)
|
Change from baseline to 12 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Hepatic fat content
Time Frame: Change from baseline to 12 weeks
|
Hepatic fat content will be assessed by Magnetic Resonance Imaging (MRI)
|
Change from baseline to 12 weeks
|
|
Change in Pancreatic fat content
Time Frame: Change from baseline to 12 weeks
|
Pancreatic fat content will be assessed by Magnetic Resonance Imaging (MRI)
|
Change from baseline to 12 weeks
|
|
Change in Intramuscular fat content
Time Frame: Change from baseline to 12 weeks
|
Intramuscular fat content will be assessed by Magnetic Resonance Imaging (MRI)
|
Change from baseline to 12 weeks
|
|
Change in Hepatic elasticity
Time Frame: Change from baseline to 12 weeks
|
Hepatic elasticity will be assessed by US elastography
|
Change from baseline to 12 weeks
|
|
Change in Pancreatic elasticity
Time Frame: Change from baseline to 12 weeks
|
Pancreatic elasticity will be assessed by US elastography
|
Change from baseline to 12 weeks
|
|
Change in Fasting glucose metabolism
Time Frame: Change from baseline to 12 weeks
|
Fasting blood samples will be used to analyse different biomarkers of glucose metabolism
|
Change from baseline to 12 weeks
|
|
Change in Fasting lipid metabolism
Time Frame: Change from baseline to 12 weeks
|
Fasting blood samples will be used to analyse different biomarkers of lipid metabolism (e.g., triglycerides, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol)
|
Change from baseline to 12 weeks
|
|
Change in Inflammatory profile
Time Frame: Change from baseline to 12 weeks
|
Fasting blood samples will be used to analyse inflammatory profile (e.g., C-reactive protein and interleukin 6)
|
Change from baseline to 12 weeks
|
|
Change in Hepatic profile
Time Frame: Change from baseline to 12 weeks
|
Fasting blood samples will be used to analyse hepatic profile (e.g., alkaline phosphatase, bilirubin, alanine transaminase and gamma-glutamyl transferase)
|
Change from baseline to 12 weeks
|
|
Change in Kidney profile
Time Frame: Change from baseline to 12 weeks
|
Fasting blood samples will be used to analyse kidney profile (e.g., creatinine and creatine kinase)
|
Change from baseline to 12 weeks
|
|
Change in Glycemia (Continuous Glucose Monitoring)
Time Frame: Change from baseline to 12 weeks
|
Glycemia will be assessed by Continuous Glucose Monitoring during 2 weeks
|
Change from baseline to 12 weeks
|
|
Change in Body weight
Time Frame: Change from baseline to 12 weeks
|
Body weight will be measured by a digital scale
|
Change from baseline to 12 weeks
|
|
Change in Body composition (Fat mass and fat free mass)
Time Frame: Change from baseline to 12 weeks
|
Body composition will be assessed by Dual-energy X-ray Absorptiometry (DXA)
|
Change from baseline to 12 weeks
|
|
Change in Anthropometric measures
Time Frame: Change from baseline to 12 weeks
|
Neck, hip and waist circumferences will be assessed by standard procedures
|
Change from baseline to 12 weeks
|
|
Change in Blood pressure
Time Frame: Change from baseline to 12 weeks
|
Systolic and Diastolic blood pressure will be assessed by standard procedures
|
Change from baseline to 12 weeks
|
|
Change in energy intake
Time Frame: Change from baseline to 12 weeks
|
Energy intake (kcal/day) will be assessed by 24h recalls
|
Change from baseline to 12 weeks
|
|
Change in macronutrients intake
Time Frame: Change from baseline to 12 weeks
|
Macronutrients intake (g/day and percentage of energy intake) will be assessed by 24h recalls
|
Change from baseline to 12 weeks
|
|
Change in dietary habits
Time Frame: Change from baseline to 12 weeks
|
Dietary habits will be assessed by food frequency questionnaires
|
Change from baseline to 12 weeks
|
|
Change in Food craving
Time Frame: Change from baseline to 12 weeks
|
Food craving will be assessed by the Food Craving Inventory (FCI)
|
Change from baseline to 12 weeks
|
|
Change in Appetitive traits
Time Frame: Change from baseline to 12 weeks
|
Appetitive traits will be assessed by the Adult Eating Behavior Questionnaire (AEBQ)
|
Change from baseline to 12 weeks
|
|
Change in Subjective sleep quality
Time Frame: Change from baseline to 12 weeks
|
Subjective sleep quality will be assessed by the Pittsburgh Sleep Quality Index (PSQI)
|
Change from baseline to 12 weeks
|
|
Change in Objectively sleep quality
Time Frame: Change from baseline to 12 weeks
|
Objectively sleep quality will be assessed by accelerometry
|
Change from baseline to 12 weeks
|
|
Change in Chronotype
Time Frame: Change from baseline to 12 weeks
|
Chronotype will be assessed by the Munich Chronotype Questionnaire (MCTQ)
|
Change from baseline to 12 weeks
|
|
Change in Morning-Evening type
Time Frame: Change from baseline to 12 weeks
|
Morning-Evening type will be assessed by the Morningness-Eveningness Questionnaire Self-Assessment Version.
|
Change from baseline to 12 weeks
|
|
Change Subjective physical activity levels
Time Frame: Change from baseline to 12 weeks
|
Subjective physical activity levels will be assessed by the International Physical Activity Questionnaire short form
|
Change from baseline to 12 weeks
|
|
Change Objectively physical activity levels
Time Frame: Change from baseline to 12 weeks
|
Objectively physical activity levels will be assessed by accelerometry
|
Change from baseline to 12 weeks
|
|
Change in Depression aspects
Time Frame: Change from baseline to 12 weeks
|
Depression aspects will be assessed by the Beck Depression Inventory Fast Screen (BDI-FS)
|
Change from baseline to 12 weeks
|
|
Change in Stress aspects
Time Frame: Change from baseline to 12 weeks
|
Stress aspects will be assessed by the Perceived Stress Scale (PSS)
|
Change from baseline to 12 weeks
|
|
Change in Anxiety aspects
Time Frame: Change from baseline to 12 weeks
|
Anxiety aspects will be assessed by the State-Trait Anxiety Inventory (STAI)
|
Change from baseline to 12 weeks
|
|
Change in General health
Time Frame: Change from baseline to 12 weeks
|
General health will be assessed by the EuroQol 5 dimensions 5 levels (EQ-5D-5L)
|
Change from baseline to 12 weeks
|
|
Change in Quality of life
Time Frame: Change from baseline to 12 weeks
|
Quality of life will be assessed by the Rand Short Form 36 (SF-36)
|
Change from baseline to 12 weeks
|
|
Change in Gut microbiota composition
Time Frame: Change from baseline to 12 weeks
|
DNA sequencing to determine gut microbiota composition (e.g., phylum and genera)
|
Change from baseline to 12 weeks
|
|
Change in Gut microbiota diversity
Time Frame: Change from baseline to 12 weeks
|
DNA sequencing to determine gut microbiota diversity (e.g., beta and alpha)
|
Change from baseline to 12 weeks
|
|
Feasibility of recruitment
Time Frame: 12 weeks
|
Feasibility of recruitment (i.e., percent of response rate).
|
12 weeks
|
|
Feasibility of the intervention
Time Frame: 12 weeks
|
Retention during the intervention (i.e., percent of attrition).
|
12 weeks
|
|
Adherence to the intervention
Time Frame: Every day during the intervention, up to 90 days
|
Adherence will be assessed by eating records
|
Every day during the intervention, up to 90 days
|
|
Genetic variants in Clock genes
Time Frame: Baseline
|
Genetic variantes in clock genes will be determined by Illumina sytem
|
Baseline
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Epigenetic changes in clock genes
Time Frame: Change from baseline to 12 weeks
|
Changes in selected CpG in clock genes will be determined by Illumina system
|
Change from baseline to 12 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Jonatan R. Ruiz, PhD, Universidad de Granada
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- EXTREME
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.